Comparison of U7snRNA-induced dystrophin expression following systemic delivery with AAV9, MyoAAV 2A, and MyoAAV 3A capsids in the Dup2 mouse

被引：0
|
作者：
Frair, E. [1 ]
Bradley, A. [1 ]
Dufresne, G. [1 ]
Sarff, J. [1 ]
Stevens, K. [1 ]
Rohan, N. [1 ]
Nicolau, S. [1 ]
Vetter, T. [1 ,2 ]
Gushchina, L. [1 ,2 ]
Flanigan, K. [1 ,2 ,3 ]
机构：
[1] Nationwide Childrens Hosp, Ctr Gene Therapy, Abigail Wexner Res Inst, Columbus, OH USA
[2] Ohio State Univ, Dept Paediat, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA
来源：
NEUROMUSCULAR DISORDERS | 2023年 / 33卷
关键词：
D O I：
10.1016/j.nmd.2023.07.140
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P13
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 9 条
  • [1] Comparison of U7snRNA-induced dystrophin expression following systemic delivery with AAV9 and AAVrh74 capsids
    Lay, J.
    Frair, E.
    Bradley, A.
    Vetter, T.
    Rohan, N.
    Bellinger, C.
    Waldrop, M.
    Wein, N.
    Gushchina, L.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S100 - S100
  • [2] A Single Neonatal Delivery of an Exon 2 Directed AAV9.U7snRNA Vector Results in Long-Term Dystrophin Expression That Prevents Pathologic Features in the Dup2 Mouse
    Wein, Nicolas
    Simmons, Tabatha R.
    Gumienny, Felecia
    Yurkoski, Jacqueline
    Huang, Nianyuan
    Muntoni, Francesco
    Flanigan, Kevin M.
    MOLECULAR THERAPY, 2016, 24 : S247 - S248
  • [3] A single neonatal delivery of an exon 2 directed AAV9.U7snRNA vector results in long-term dystrophin expression that prevents pathologic features in the Dup2 mouse
    Wein, N.
    Simmons, T.
    Gumienny, F.
    Yurkoski, J.
    Huang, N.
    Muntoni, F.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S126 - S127
  • [4] Intravenous Delivery of a rAAV9 U7snRNA Vector Targeting Exon 2 Results in Widespread Dystrophin Expression in the Dup2 DMD mouse model
    Simmons, Tabatha R.
    Vulin, Adeline
    Wein, Nicolas
    Rutherford, Andrea M.
    Janssen, Paul M.
    Flanigan, Kevin M.
    MOLECULAR THERAPY, 2014, 22 : S51 - S51
  • [5] Prolonged Exon 2 Skipping and Robust Dystrophin Expression 1 Year Post Single Neonatal Injection of an AAV9. U7snRNA Vector in the Dup2 Mouse
    Wein, Nicolas
    Simmons, Tabatha
    Gumienny, Felecia
    Huang, Nianyuan
    Heller, Kristin
    Rodino-Klapac, Louise
    Muntoni, Francesco
    Flanigan, Kevin
    MOLECULAR THERAPY, 2017, 25 (05) : 19 - 19
  • [6] Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model
    Gushchina, Liubov, V
    Bradley, Adrienne J.
    Vetter, Tatyana A.
    Lay, Jacob W.
    Rohan, Natalie L.
    Frair, Emma C.
    Wein, Nicolas
    Flanigan, Kevin M.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 31
  • [7] Systemic delivery of an AAV9 exon- skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
    Wein, Nicolas
    Vetter, Tatyana A.
    Vulin, Adeline
    Simmons, Tabatha R.
    Frair, Emma C.
    Bradley, Adrienne J.
    V. Gushchina, Liubov
    Almeida, Camila F.
    Huang, Nianyuan
    Lesman, Daniel
    Rajakumar, Dhanarajan
    Weiss, Robert B.
    Flanigan, Kevin M.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2022, 26 : 279 - 293
  • [8] Restoration of Full-Length Dystrophin Expression in the Dup2 Mouse Induced by Systemic Delivery of a Peptide-Conjugated Morpholino Oligomer
    Gushchina, Liubov V.
    Grounds, Kelly M.
    Huang, Nianyuan
    Frair, Emma
    Schnell, Frederick J.
    Hanson, Gunnar J.
    Simmons, Tabatha
    Wein, Nicolas
    Flanigan, Kevin M.
    MOLECULAR THERAPY, 2020, 28 (04) : 20 - 20
  • [9] A single neonatal injection of an AAV9.U7snRNA virus mediating skipping of dmd exon 2 allows dystrophin expression preventing apparition of pathologic features in the Dup2 mouse one year post injection
    Wein, N.
    Simmons, T.
    Gumienny, F.
    Huang, N.
    Heller, K.
    Yurkoski, J.
    Rodino-Klapac, L.
    Muntoni, F.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S187 - S187
1